A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer
Open Access
- 1 February 2015
- journal article
- review article
- Published by Elsevier BV in Translational Oncology
- Vol. 8 (1), 18-24
- https://doi.org/10.1016/j.tranon.2014.11.003
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon CancerJNCI Journal of the National Cancer Institute, 2012
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Roles of VEGF-C and Smad4 in the Lymphangiogenesis, Lymphatic Metastasis, and Prognosis in Colon CancerJournal of Gastrointestinal Surgery, 2011
- TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective studyBMC Cancer, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Evaluation of the Quality of Prognosis Studies in Systematic ReviewsAnnals of Internal Medicine, 2006
- Frequent loss of SMAD4/DPC4 protein in colorectal cancersGut, 2002
- Extracting summary statistics to perform meta-analyses of the published literature for survival endpointsStatistics in Medicine, 1998
- Frequency of Smad gene mutations in human cancers.1997
- Identification of a Chromosome 18q Gene that Is Altered in Colorectal CancersScience, 1990